Valeant Pharmaceuticals International, Inc. 4
4 · Valeant Pharmaceuticals International, Inc. · Filed Jul 2, 2015
Insider Transaction Report
Form 4
Rosiello Robert L.
EVP, Chief Financial Officer
Transactions
- Award
Restricted Share Units
2015-07-01+204,000→ 420,900 total - Award
Restricted Share Units
2015-07-01+204,000→ 216,900 total
Footnotes (4)
- [F1]This number represents the maximum number of performance-based Restricted Share Units ("PSUs") that can be paid out, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). See note (2).
- [F2]The PSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $230.82 (i.e., at 10% each vesting RSU earns one Common Share and at 30% each vesting RSU earns three Common Shares) on each of three measurement dates: 25% would vest on April 1, 2018, 50% on July 1, 2018 and 25% on October 1, 2018 with early vesting possible at higher TSR levels.
- [F3]This number represents the maximum number of performance-based Restricted Share Units ("PSUs") that can be paid out, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant"). See note (4).
- [F4]The PSUs are eligible to vest on the achievement of TSR targets ranging from 10% to 30% over a base price of $230.82 (i.e., at 10% each vesting RSU earns one Common Share and at 30% each vesting RSU earns three Common Shares) on each of three measurement dates: 25% would vest on April 1, 2020, 50% on July 1, 2020 and 25% on October 1, 2020 with early vesting possible at higher TSR levels.